RxDoctor Payments Data

Mary Klunick, NP

Family · Springfield, ILNPI 1083130298

Payments from drug & device makers

$4,298in general payments, 2019–2025

Across 195 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$860
  • Johnson & Johnson$269
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$225
  • Madrigal Pharmaceuticals$183
  • Janssen Scientific Affairs, LLC$154
  • plus $419 from 10 others

What the payments were for

  • Food & beverage$4,18697%
  • Education$1123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,298 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$36,913
Medicare patients
380
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase31$122,732
LinzessLinaclotide22$20,912
Mesalamine17$13,814
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates173$10,902
Mesalamine ErMesalamine21$10,507
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C30$4,244
ClenpiqSod Picosulf/Mag Ox/Citric Ac17$2,935
Famotidine389$2,425
Budesonide DrBudesonide21$2,313
Dicyclomine Hcl115$2,300
Pantoprazole Sodium166$2,297
Sucralfate51$2,012
Omeprazole195$1,773
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine35$1,526
CholestyramineCholestyramine (With Sugar)19$1,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,189$143,64453 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$225$4,24430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.

Other family in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →